Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 16, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 18, 2026
DirectorIndirect holdingOther
Context
Classification
other
Code J — not an open-market trade
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-467195
Filed / recorded
Nov 18, 2026, 9:34 PM UTC
Added to OQRO
Nov 18, 2026, 9:37 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
SpyGlass Pharma, Inc.
Issuer CIK
1778922
Ticker
SGP
Reporting person
Kirk G. Nielsen
Relationship
Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Nov 16, 2026
Transaction code
J
Shares / units
331,036
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
2,979,583
Ownership form
Indirect — See footnote
Amendment
No
Footnotes from the filing
Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Vensana Capital I, L.P. ("Vensana I") to its partners.
These shares are held directly by Vensana I. Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Spyglass Pharma's L.P., Insider told the SEC about a plan to sell $1.17M of Spyglass Pharma shares around Nov 18, 2026. The shares were not acquired as compensation. That is 0.1% of all Spyglass Pharma shares.
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade. A share price line is a session where the close moved at least 10% and four times its usual daily change.
The company's last weighty Form 8-K report up to this date: reported its results, 5 days earlier (Nov 11, 2026).